Anti-Reflux Mucosal Ablation(ARMA) and Anti-Reflux Mucosectomy(ARMS) in Gastroesophageal Reflux Disease

Launched by TAIPEI VETERANS GENERAL HOSPITAL, TAIWAN · Jun 13, 2022

Keywords

ClinConnect Summary

This clinical trial is studying two different treatments for people with gastroesophageal reflux disease (GERD), which is a condition where stomach acid frequently flows back into the esophagus, causing discomfort. The trial aims to compare the effects of two procedures, called Anti-Reflux Mucosal Ablation (ARMA) and Anti-Reflux Mucosectomy (ARMS), on patients' health over time. Researchers want to understand how these treatments affect healing, the need for medication, quality of life, emotional well-being, sleep quality, and changes in bacteria in the digestive system.

To be eligible for this trial, participants should be between 20 and 75 years old and have had GERD for at least a year. However, there are some exclusions: people with a high body weight, certain esophageal conditions, or those who are pregnant or have had specific surgeries are not eligible. If you decide to participate, you can expect to undergo one of the treatments and be monitored for various health changes. This study is not yet recruiting participants, so there will be more information available soon for those interested in joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 20-75 years of age,
• • History of GERD over 1 year
• Exclusion Criteria:
• • body mass index (BMI) \> 35
• • Hiatal hernia \> 2cm
• • Esophageal ulcer
• • Esophageal stricture
• • Barrett's esophagus (Prague criteria: C\>1cm, M\>=2cm)
• • Major esophageal motility disorders
• • Gastroparesis
• • Pregnancy or plans for pregnancy in the next 12 months
• • Immunosuppressive therapy
• • Cirrhosis
• • Portal hypertension and/or varices
• • Previous gastric or esophageal surgery
• • Esophageal diverticulum
• • Scleroderma or dermatomyositis
• • Coagulation disorders
• • Anti-platelet or anticoagulants use